0001171843-21-001522.txt : 20210304 0001171843-21-001522.hdr.sgml : 20210304 20210304073212 ACCESSION NUMBER: 0001171843-21-001522 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210304 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210304 DATE AS OF CHANGE: 20210304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980597776 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 21712585 BUSINESS ADDRESS: STREET 1: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_030421.htm FORM 8-K Form 8-K
0001447028 False 0001447028 2021-03-04 2021-03-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 4, 2021

_______________________________

Arbutus Biopharma Corporation

(Exact name of registrant as specified in its charter)

_______________________________

British Columbia, Canada001-3494998-0597776
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

701 Veterans Circle

Warminster, Pennsylvania 18974

(Address of Principal Executive Offices) (Zip Code)

(267) 469-0914

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, without par valueABUSThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On March 4, 2021, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2020 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description
   
99.1 Press release dated March 4, 2021
104 Cover page interactive data file (formatted as inline XBRL).
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Arbutus Biopharma Corporation
   
  
Date: March 4, 2021By: /s/ David C. Hastings        
  David C. Hastings
  Chief Financial Officer
  

 

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data

Reductions in HBsAg seen in both HBV DNA negative and HBV DNA positive subjects support a potential dosing schedule for AB-729 as infrequently as every 8 to 12 weeks

Several AB-729 Phase 2 proof-of-concept combination clinical trials expected to initiate this year

AB-836, Arbutus’ proprietary oral capsid inhibitor, on track to begin a Phase 1a/1b clinical trial in healthy volunteers and subjects with HBV in the first half of 2021

Conference Call and Webcast Scheduled Today at 8:45 AM ET

WARMINSTER, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today reports its fourth quarter and year-end 2020 financial results and provides a corporate update.

William Collier, President and Chief Executive Officer of Arbutus, stated, “Our current data set for AB-729, our lead compound in development for HBV, has grown substantially over the past 12 months and increases our confidence that it has the potential to be a cornerstone drug in future HBV combination regimens.”

Mr. Collier added, “Looking ahead, 2021 is expected to provide us with important insights regarding the potential therapeutic value of several compounds in our proprietary HBV pipeline including: longer term Phase 1a/1b dosing results for AB-729; the initiation of a Phase 2 combination clinical trial with AB-729 and Assembly Biosciences’ lead core inhibitor; initiation of Phase 2 clinical trials for AB-729 and one or more approved or investigational agents; and initial Phase 1a/1b data from our proprietary oral capsid inhibitor, AB-836.”

Dr. Gaston Picchio, Chief Development Officer of Arbutus, commented, “AB-729 has shown impressive reductions in HBsAg with an unremarkable longer term safety profile in the clinical data from our Phase 1a/1b clinical trial. The data that has emerged from this clinical trial so far is encouraging and it suggests that AB-729 could potentially be dosed less frequently than every 4 weeks potentially providing a competitive advantage. As a matter of fact, we are testing a dosing schedule of every 8 weeks in our Phase 2 clinical trial in collaboration with Assembly.”

Dr. Picchio added, “We are pleased that we have initiated screening for our proof-of-concept Phase 2 clinical trial combining AB-729 with Assembly Biosciences’ lead core inhibitor candidate, also known as a capsid inhibitor, vebicorvir, and a nucleos(t)ide reverse transcriptase inhibitor.”

Pipeline Update

AB-729

  • Arbutus is currently conducting a single- and multi-dose Phase 1a/1b clinical trial to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB-729 in healthy subjects and in subjects with chronic HBV infection.

  • Results to date demonstrate that treatment of AB-729 using the 60 mg and 90 mg doses has been well tolerated after a single dose. Efficacy results to date suggest that repeat dosing using the 60 mg dose every 4 weeks resulted in a continuous and robust mean HBsAg decline at week 24 (-1.84 log10 IU/mL, N=7). Repeat dosing using the 60 mg dose every 8 weeks results in comparable mean HBsAg declines relative to the 60 mg dose every 4 weeks at week 16 (-1.37 log10 IU/mL vs -1.44 log10 IU/mL, p<0.7). In HBV DNA positive CHB subjects, a single 90 mg AB-729 dose resulted in robust mean HBsAg (-1.02 log10 IU/mL) and HBV DNA (-1.53 log10 IU/mL) declines at week 12, as well as decreases in HBV RNA and core-related antigen. Similar mean HBsAg reductions were observed in HBV DNA positive and negative CHB subjects supporting complete target engagement by AB-729.

  • Arbutus expects to provide additional data from ongoing cohorts of the Phase 1a/1b clinical trial in the first half of 2021, except for initial data from the 90 mg every 12 week cohort which is expected in the second half of 2021. Based on these results, Arbutus intends to advance AB-729 into two Phase 2 combination trials with one or more approved or investigational agents in the second half of 2021 with dosing of AB-729 as infrequently as every 8 or 12 weeks.

  • Arbutus and Assembly initiated screening in a Phase 2 proof-of-concept combination clinical trial to evaluate AB-729 in combination with Assembly Biosciences’ lead core (capsid) inhibitor candidate vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor for the treatment of subjects with chronic HBV infection. The randomized, multi-center, open-label Phase 2 clinical trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triple combination of VBR, AB-729 and an NrtI compared to the double combinations of VBR with an NrtI and AB-729 with an NrtI. Approximately 60 virologically-suppressed subjects with HBeAg negative chronic HBV are expected to be enrolled in the first cohort of the trial. Subjects will be dosed for 48 weeks with VBR 300 mg orally once daily and AB-729 60 mg subcutaneously every 8 weeks, with a 48-week follow-up period.

AB-836: Oral Capsid Inhibitor

  • In January 2020, Arbutus selected AB-836 as its next-generation oral capsid inhibitor. AB-836 is from a novel chemical series differentiated from competitor compounds with the potential for increased efficacy and an enhanced resistance profile. Arbutus completed CTA/IND-enabling studies in the fourth quarter of 2020 and anticipates initiating a Phase 1a/1b clinical trial for AB-836 in the first half of 2021.

Early R&D Programs

  • Arbutus’ drug discovery efforts are focused on follow-on compounds for its current HBV pipeline and new small molecule antiviral medicines to treat COVID-19 and future coronavirus outbreaks. Arbutus expects to continue to advance its research in its oral PD-L1 inhibitor, RNA-destabilizer and coronavirus programs.

Genevant Sciences Ltd.

Arbutus owns approximately 16% of the common equity of Genevant Sciences Ltd. (“Genevant”), a company Arbutus launched with Roivant Sciences, Ltd. and to which Arbutus licensed exclusive rights to its lipid nanoparticle ("LNP") and ligand conjugate delivery technologies for RNA-based applications outside of HBV. We are entitled to receive tiered low single-digit royalties on future sales of Genevant products covered by the licensed patents. If Genevant sub-licenses the intellectual property licensed by us to Genevant, we are entitled to receive, upon the commercialization of a product developed by such sub-licensee, the lesser of (i) twenty percent of the revenue received by Genevant for such sublicensing and (ii) tiered low single-digit royalties on product sales by the sublicensee.

Financial Results

Cash, Cash Equivalents and Investments

Arbutus had cash, cash equivalents and investments totaling $123.3 million as of December 31, 2020, as compared to $90.8 million as of December 31, 2019. During the twelve months ended December 31, 2020, Arbutus used $51.4 million in operating activities and made a $2.5 million equity investment in Genevant, which was offset by $86.3 million of net proceeds from the issuance of common shares under Arbutus’ ATM program. Thus far during the first quarter of 2021, Arbutus has received an additional $24.3 million of net proceeds from the issuance of common shares under its ATM program. Arbutus expects a net cash burn between $70 to $75 million in 2021 and therefore the Company believes its cash runway extends through the third quarter of 2022.

Net Loss

Net loss attributable to common shares for the twelve months ended December 31, 2020 was $75.9 million ($1.00 basic and diluted loss per common share) as compared to $164.9 million ($2.89 basic and diluted loss per common share) for the twelve months ended December 31, 2019. The decrease in the net loss was due primarily to: i) non-cash impairment charges in 2019 of $43.8 million for an in-process research and development ("IPR&D") intangible asset and $22.5 million for goodwill to reduce their carrying values to zero, as well as a corresponding income tax benefit of $12.7 million related to the decrease in the deferred tax liability associated with the IPR&D intangible assets; ii) a $20.0 million decrease in non-cash equity losses associated with the Company’s investment in Genevant; iii) a $10.1 million decrease in research and development expenses; and iv) a $6.3 million expense in 2019 related to an arbitration award from the Company's arbitration with the University of British Columbia.

Net loss attributable to common shares for the twelve months ended December 31, 2020 and 2019 also included non-cash expense for the accrual of coupon on the Company’s convertible preferred shares of $12.1 million and $11.1 million, respectively.

Operating Expenses

Research and development expenses were $47.5 million for the twelve months ended December 31, 2020 compared to $57.6 million in 2019. The decrease in research and development expenses for the year ended December 31, 2020 versus the same period in 2019 was due primarily to lower clinical expenses in 2020. General and administrative expenses were $14.7 million for the twelve months ended December 31, 2020 compared to $17.7 million for the same period in 2019. This decrease was due primarily to $2.3 million in cash severance and $1.1 million of non-cash stock-based compensation expense related to our former President and Chief Executive Officer’s departure from the Company in June 2019.

Outstanding Shares

The Company had approximately 89.7 million common shares issued and outstanding as of December 31, 2020. In addition, the Company had approximately 10.7 million stock options outstanding and 1.164 million convertible preferred shares outstanding, which (including the annual 8.75% coupon) will be mandatorily convertible into approximately 23 million common shares on October 18, 2021.

COVID-19 Impact

In December 2019 an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to nearly every country in the world. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. A number of countries and other jurisdictions around the world have implemented extreme measures to try and slow the spread of the virus. These measures include the closing of businesses and requiring people to stay in their homes, the latter of which raises uncertainty regarding the ability to travel to hospitals in order to participate in clinical trials. Additional measures that have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, include shortages and delays in the supply chain, and prohibitions in certain countries on enrolling subjects in new clinical trials. While we have been able to progress with our clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will negatively impact our plans and timelines in the future.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS
(in thousands, except share and per share data)

 Year ended December 31,
 2020 2019
Revenue   
Collaborations and licenses$3,519  $4,355 
Non-cash royalty revenue3,395  1,656 
Total revenue6,914  6,011 
Operating expenses   
Research and development47,481  57,601 
General and administrative14,724  17,727 
Depreciation1,978  2,028 
Change in fair value of contingent consideration473  (173)
Site consolidation64  156 
Impairment of intangible assets  43,836 
Impairment of goodwill  22,471 
Arbitration  6,266 
Loss from operations(57,806) (143,901)
Other income (loss)   
Interest income741  2,111 
Interest expense(4,011) (2,108)
Equity investment loss(2,545) (22,522)
Foreign exchange gain (loss)(124) 41 
Total other loss(5,939) (22,478)
Income tax benefit  12,656 
Net loss$(63,745) $(153,723)
Dividend accretion of convertible preferred shares(12,123) (11,149)
Net loss attributable to common shares$(75,868) $(164,872)
Loss per share   
Basic and diluted$(1.00) $(2.89)
Weighted average number of common shares   
Basic and diluted75,835,378  57,093,454 


 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

 December 31, 2020 December 31, 2019
Cash, cash equivalents and marketable securities, current$123,268 $90,834
Accounts receivable and other current assets4,436 2,994
Total current assets127,704 93,828
Property and equipment, net of accumulated depreciation6,927 8,676
Right of use asset2,405 2,738
Other non-current assets 44  293
Total assets$
137,080 $
105,535
Accounts payable and accrued liabilities$8,901 $7,235
Liability-classified options 
250  
253
Lease liability, current390 340
Total current liabilities9,541 7,828
Liability related to sale of future royalties19,554 18,992
Contingent consideration3,426 2,953
Lease liability, non-current2,593 3,018
Total stockholders' equity101,966 72,744
Total liabilities and stockholders' equity$137,080 $105,535



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(in thousands)

 Year ended December 31,
 2020 2019
Net loss$(63,745) $(153,723)
Deferred income tax benefit  (12,661)
Impairment of intangible assets and goodwill  66,307 
Net equity investment loss2,545  22,522 
Other non-cash items9,328  8,774 
Changes in working capital431  (2,225)
Net cash used in operating activities$(51,441) $(71,006)
Net cash provided by (used in) investing activities(14,909) 28,338 
Net cash provided by financing activities86,746  37,457 
Effect of foreign exchange rate changes on cash and cash equivalents56  68 
Increase (decrease) in cash and cash equivalents$20,452  $(5,143)
Cash and cash equivalents, beginning of period31,799  36,942 
Cash and cash equivalents, end of period$52,251  $31,799 
Investments$71,017  $59,035 
Total cash, cash equivalents and investments, end of period$123,268  $90,834 

Conference Call and Webcast Today

Arbutus will hold a conference call and webcast today, Thursday, March 4, 2021 at 8:45 AM Eastern Time to provide a corporate update. You can access a live webcast of the call, which will include presentation slides, through the Investors section of Arbutus’ website at http://www.arbutusbio.com or directly at Live Webcast. Alternatively, you can dial (866) 393-1607 or (914) 495-8556 and reference conference ID 4084504.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 4084504.

About AB-729

AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes using Arbutus’ novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. AB-729 inhibits viral replication and reduces all HBV antigens, including hepatitis B surface antigen in preclinical models. Reducing hepatitis B surface antigen is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. Based upon clinical data generated thus far in an ongoing single- and multi-dose Phase 1a/1b clinical trial, AB-729 has demonstrated positive safety and tolerability data and meaningful reductions in hepatitis B surface antigen.

About AB-836

AB-836 is an oral HBV capsid inhibitor. HBV core protein assembles into a capsid structure, which is required for viral replication. The current standard-of-care therapy for HBV, primarily nucleos(t)ide analogues that work by inhibiting the viral polymerase, significantly reduce virus replication, but not completely. Capsid inhibitors inhibit replication by preventing the assembly of functional viral capsids. They also have been shown to inhibit the uncoating step of the viral life cycle thus reducing the formation of new covalently closed circular DNA (cccDNA), the genetic reservoir which the virus uses to replicate itself.

About HBV

Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Forward-Looking Statements and Information

This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about our confidence that AB-729 has the potential to be a cornerstone drug in future HBV combination regimens; the potential that AB-729 could potentially be dosed less frequently than every 4 weeks potentially providing a competitive advantage; our expectation to provide additional data from ongoing cohorts of the Phase 1a/1b clinical trial of AB-729 in the first half of 2021, except for initial data from the 90 mg every 12 week cohort which is expected in the second half of 2021; our intention to advance AB-729 into two Phase 2 combination trials with one or more approved or investigational agents in the second half of 2021 with dosing of AB-729 as infrequently as every 8 to 12 weeks; our plans with respect to the Phase 2 proof-of-concept combination clinical trial to evaluate AB-729 in combination with Assembly Biosciences’ lead core/capsid inhibitor candidate vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor for the treatment of subjects with chronic HBV infection, including the expected trial design, the expected number and type of patients to be enrolled in the trial and the expected dosing schedule; the potential for AB-836 to have increased efficacy and an enhanced resistance profile; the expected initiation, in the first half of 2021, of a Phase 1a/1b clinical trial of AB-836; the expected continued advancement of our research in the oral PD-LE inhibitor, RNA-destabilizer and coronavirus programs; our expectation regarding the impact of the COVID-19 pandemic on our business and clinical trials; our expected net cash burn between $70 to $75 million for 2021; and our expected cash runway through the third quarter of 2022.

With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies, including uncertainties and contingencies related to the ongoing COVID-19 pandemic.

Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; market shifts may require a change in strategic focus; and the ongoing COVID-19 pandemic could significantly disrupt Arbutus’ clinical development programs.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_030421_htm.xml IDEA: XBRL DOCUMENT 0001447028 2021-03-04 2021-03-04 iso4217:USD shares iso4217:USD shares 0001447028 false 8-K 2021-03-04 Arbutus Biopharma Corporation A1 001-34949 98-0597776 701 Veterans Circle Warminster PA 18974 267 469-0914 false false false false Common Shares, without par value ABUS NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Mar. 04, 2021
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 04, 2021
Entity File Number 001-34949
Entity Registrant Name Arbutus Biopharma Corporation
Entity Central Index Key 0001447028
Entity Tax Identification Number 98-0597776
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 701 Veterans Circle
Entity Address, City or Town Warminster
Entity Address, State or Province PA
Entity Address, Postal Zip Code 18974
City Area Code 267
Local Phone Number 469-0914
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol ABUS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_030421.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_030421.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_030421.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_030421.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_030421.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-21-001522-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-21-001522-xbrl.zip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�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end